AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
Shun Lu, Yan Yu, Jun Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
The AdvanTIG-105 study evaluated the combination of ociperlimab and tislelizumab, with or without chemotherapy, in patients with metastatic non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). This phase I/Ib trial included various patient cohorts, revealing an overall response rate (ORR) of 55.0% in untreated squamous NSCLC and 65.9% in untreated ES-SCLC, indicating promising preliminary antitumor activity.
Key findings
- Objective response rates were 55.0% for untreated squamous NSCLC and 65.9% for untreated ES-SCLC.
- Median duration of response was 16.9 months for untreated squamous NSCLC and 4.1 months for untreated ES-SCLC.
- Median progression-free survival was 8.2 months for untreated squamous NSCLC and 4.9 months for untreated ES-SCLC.
- Treatment-related adverse events occurred in 95.1% of untreated squamous NSCLC patients.
Why it matters
The study highlights the potential of combining ociperlimab and tislelizumab in treating advanced lung cancers, which are typically associated with poor outcomes. Understanding these preliminary results can inform future treatment strategies and clinical trials.